← Leaderboards
Serena Patricia Koenig
Brigham And Women'S Hospital
$7,375,882
Attributed
$9,734,200
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,734,200 · 5
By mechanism
U01$4,716,636 · 1
R01$3,591,933 · 2
K01$878,040 · 1
R34$547,591 · 1
Top collaborators
- Sean Adam Wasserman6 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Kenneth H Mayer$64,411,257
- David J. Kwiatkowski$31,996,627
- Bradley E Bernstein$49,054,379
- Hadine Joffe$12,089,762
- Louise Catherine Ivers$9,002,450
Others in their field
Top investigators on “Antiretroviral Therapy”
- James Dennis Neaton · Northwestern University$279,044,427
- Lawrence Corey · Fred Hutchinson Cancer Center$278,220,635
- Constance Ann Benson · University Of California, San Diego$241,336,455
- Carol Nesel · Westat$188,148,170
- Judith S. Currier · University Of California Los Angeles$182,467,520
- Barbara Driver · Westat, Inc.$170,789,549
Research focus
Antiretroviral TherapyGuidelinesHaitiWorld Health OrganizationClinical TrialsStandard CareParticipantRandomizedPharmaceutical PreparationsFollow-UpAdultResourcesEvaluationCostCost EffectivenessTuberculosisDrug ResistanceBaseMonitorCaringAdverse EventPatient PopulationSouth AfricaFuture
Grant awards (22)
PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis$406,451
U01 · FY2025 · AI · contact PI
PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis$398,334
U01 · FY2025 · AI · contact PI
PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis$366,165
U01 · FY2025 · AI · contact PI
PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis$1,143,959
U01 · FY2024 · AI · contact PI
PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis$1,180,713
U01 · FY2023 · AI · contact PI
PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis$1,221,014
U01 · FY2022 · AI · contact PI
Immediate Fast-Track versus Standard Care for Persons Living with HIV in Haiti: A Randomized Pilot Study$117,745
R34 · FY2020 · MH · contact PI
A Trial of Same-Day Testing and Treatment to Improve Outcomes among Symptomatic Patients Newly Diagnosed with HIV$553,489
R01 · FY2019 · AI · contact PI
Immediate Fast-Track versus Standard Care for Persons Living with HIV in Haiti: A Randomized Pilot Study$238,204
R34 · FY2019 · MH · contact PI
A Trial of Same-Day Testing and Treatment to Improve Outcomes among Symptomatic Patients Newly Diagnosed with HIV$563,210
R01 · FY2018 · AI · contact PI
Immediate Fast-Track versus Standard Care for Persons Living with HIV in Haiti: A Randomized Pilot Study$191,642
R34 · FY2018 · MH · contact PI
A Trial of Same-Day Testing and Treatment to Improve Outcomes among Symptomatic Patients Newly Diagnosed with HIV$590,974
R01 · FY2017 · AI · contact PI
Same-Day HIV Testing and Treatment Initiation to Improve Retention in Care$609,478
R01 · FY2015 · AI · contact PI
Same-Day HIV Testing and Treatment Initiation to Improve Retention in Care$611,547
R01 · FY2014 · AI · contact PI
Same-Day HIV Testing and Treatment Initiation to Improve Retention in Care$663,235
R01 · FY2013 · AI · contact PI
Cost-effectiveness of Early vs. Delayed Antiretroviral Therapy in Haiti$125,377
K01 · FY2011 · TW · contact PI
Cost-effectiveness of Early vs. Delayed Antiretroviral Therapy in Haiti$124,616
K01 · FY2010 · TW · contact PI
Cost-effectiveness of Early vs. Delayed Antiretroviral Therapy in Haiti$123,854
K01 · FY2009 · TW · contact PI
Health Outcomes/Cost of Early vs Delayed ART in Haiti$120,433
K01 · FY2007 · TW · contact PI
Health Outcomes/Cost of Early vs Delayed ART in Haiti$128,120
K01 · FY2006 · TW · contact PI
Health Outcomes/Cost of Early vs Delayed ART in Haiti$128,120
K01 · FY2005 · TW
Health Outcomes/Cost of Early vs Delayed ART in Haiti$127,520
K01 · FY2004 · TW